Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 22;325(24):2500-2502.
doi: 10.1001/jama.2021.6564.

Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

Li Tang  1 , Diego R Hijano  2 , Aditya H Gaur  2 , Terrence L Geiger  3 , Ellis J Neufeld  4 , James M Hoffman  5 , Randall T Hayden  3
Affiliations

Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

Li Tang et al. JAMA. .

Abstract

This study aims to describe an association between the Pfizer-BioNTech (BNT162b2) vaccine and decreased risk of symptomatic and asymptomatic infections with SARS-CoV-2 in hospital employees.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Neufeld reported serving as a consultant to Pfizer outside the submitted work. Dr Hayden reported serving on advisory boards for Roche Molecular, Quidel Corporation, and Inflammatix outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Cumulative Incidence of COVID-19 Against SARS-CoV-2 Infections After the First Dose
A total of 2165 unvaccinated employees and 3052 vaccinated employees were included. A, Any SARS-CoV-2 infection among St Jude employees during follow-up. B, Asymptomatic infections identified through routine asymptomatic screening; SARS-CoV-2 cases through testing based on the presence of symptoms or known COVID-19 exposure were treated as competing risks. C, Positive results via testing based on the presence of symptoms or known COVID-19 exposure; positive results from asymptomatic screening were treated as competing risks. Shaded areas are 95% CIs.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-877. doi:10.1016/S0140-6736(21)00448-7 - DOI - PMC - PubMed
    1. Dagan N, Barda N, Kepten E, et al. . BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-1423. doi:10.1056/NEJMoa2101765 - DOI - PMC - PubMed
    1. State of Tennessee Health Department. COVID-19 vaccination plan. Posted March 8, 2021. Accessed March 21, 2021. https://www.tn.gov/content/dam/tn/health/documents/cedep/novel-coronavir...
    1. Hightower AW, Orenstein WA, Martin SM. Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy. Bull World Health Organ. 1988;66(1):99-105. - PMC - PubMed

Publication types